3 research outputs found
Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
Sorafenib is an oral angiogenetic multikinase inhibitor approved in the treatment of renal and hepatocellular carcinoma. Bleeding and venous thrombotic events have been described with angiogenetic agents but cerebrovascular accidents are rarely reported. We report two cases of patients with hepatocellular carcinoma who developed a cerebrovascular accident while on sorafenib. Neither patient had any risk factors for the cerebrovascular events apart from gender and age in the second patient. Laboratory data were noncontributory. The head CT scan did not reveal acute abnormalities. No hemodynamically significant stenosis was visible in the carotid ultrasound, and the echocardiogram showed normal size of the heart chambers and normal systolic function of the left ventricle. Sorafenib was discontinued in both cases. Physicians should monitor patients receiving sorafenib for neurologic symptoms, and in the absence of other etiology, prompt discontinuation of this drug should be considered
Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
Sorafenib is an oral angiogenetic multikinase inhibitor approved in the
treatment of renal and hepatocellular carcinoma. Bleeding and venous
thrombotic events have been described with angiogenetic agents but
cerebrovascular accidents are rarely reported. We report two cases of
patients with hepatocellular carcinoma who developed a cerebrovascular
accident while on sorafenib. Neither patient had any risk factors for
the cerebrovascular events apart from gender and age in the second
patient. Laboratory data were noncontributory. The head CT scan did not
reveal acute abnormalities. No hemodynamically significant stenosis was
visible in the carotid ultrasound, and the echocardiogram showed normal
size of the heart chambers and normal systolic function of the left
ventricle. Sorafenib was discontinued in both cases. Physicians should
monitor patients receiving sorafenib for neurologic symptoms, and in the
absence of other etiology, prompt discontinuation of this drug should be
considered